Aihara Yasuo, Tsuruta Toshihisa, Kawamata Takakazu, Kanno Hitoshi, Maebayashi Katsuya, Sakauchi Masako, Wada Emiko, Osawa Makiko, Fujii Hisaichi, Kubo Osami, Hori Tomokatsu
Departments of Neurosurgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
J Pediatr Hematol Oncol. 2010 Mar;32(2):e70-4. doi: 10.1097/MPH.0b013e3181c46b92.
We performed double high-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT) in 3 children with medulloblastoma and primary leptomeningial dissemination, including spinal metastasis. After resection of the main tumor mass, 30.6 Gy whole craniospinal radiation therapy and 4 or 5 courses of conventional chemotherapy with vincristine (1.5 mg/m), carboplatin (560 mg/m), ifosfamide (9000 mg/m), and etoposide (500 mg/m), and 2 courses of high-dose thiotepa (680 mg/m) and melphalan (240 mg/m) therapy with PBSCT were administered. Two patients with low erythroblastic leukemia viral oncogene homolog 2 (ERBB2) gene expression achieved long-term survival (41 mo and 40 mo) but the patient with high ERBB2 expression relapsed 9 months after the second PBSCT.
我们对3例患有髓母细胞瘤并伴有原发性软脑膜播散(包括脊髓转移)的儿童进行了双高剂量化疗,随后进行外周血干细胞移植(PBSCT)。在切除主要肿瘤块后,给予30.6 Gy的全颅脊髓放射治疗以及4或5个疗程的常规化疗,化疗药物包括长春新碱(1.5 mg/m²)、卡铂(560 mg/m²)、异环磷酰胺(9000 mg/m²)和依托泊苷(500 mg/m²),并进行了2个疗程的高剂量噻替派(680 mg/m²)和美法仑(240 mg/m²)治疗及PBSCT。2例红细胞生成素受体2(ERBB2)基因表达低的患者获得了长期生存(41个月和40个月),但ERBB2表达高的患者在第二次PBSCT后9个月复发。